Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
161 hedge funds and large institutions have $5.9B invested in Centessa Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 50 increasing their positions, 44 reducing their positions, and 33 closing their positions.
64% more capital invested
Capital invested by funds: $3.6B → $5.9B (+$2.3B)
48% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 33
38% more call options, than puts
Call options by funds: $31.9M | Put options by funds: $23.2M
33% more funds holding in top 10
Funds holding in top 10: 12 → 16 (+4)
14% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 44
10% more funds holding
Funds holding: 146 → 161 (+15)
3.3% more ownership
Funds ownership: 97.25% → 100.55% (+3.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$209M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$94M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$91.4M |
| 4 |
Morgan Stanley
New York
|
+$80.8M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$73.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GA
General Atlantic
New York
|
-$122M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$98.2M |
| 3 |
ACA
Avoro Capital Advisors
New York
|
-$79.9M |
| 4 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$76.1M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$60.3M |
CNTA Hedge Fund Activity: Q1 2026 in Review
161 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q1 2026, worth a combined $5.9B — up 64% from $3.6B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new CNTA positions and 33 closed out — a net gain of 16 holders — while 50 added to existing stakes and 44 trimmed.
The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $209M. The largest seller was General Atlantic, cutting an estimated $122M.
- 161 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q1 2026, up from 146 in Q4 2025.
- Funds reported $5.9B of Centessa Pharmaceuticals stock for Q1 2026, up 64% quarter-over-quarter.
- 49 funds opened new Centessa Pharmaceuticals positions in Q1 2026 and 33 closed out, a net change of +16 holders.
- The largest Centessa Pharmaceuticals buyer in Q1 2026 was Pentwater Capital Management, an estimated $209M added.
- The largest Centessa Pharmaceuticals seller in Q1 2026 was General Atlantic, an estimated $122M sold.
Based on aggregated 13F filings for Q1 2026.